AYA.AX stock opened pre-market at A$3.21, up 2.88% on 28 Mar 2026 after steady volume of 376,310 shares. Artrya Limited (AYA.AX) on the ASX is an Australian healthcare AI company that sells Salix, its cloud AI for coronary CT angiography. Today’s price sits below the 50-day average A$3.49 and above the 200-day average A$2.71, keeping momentum mixed. We analyse financials, technicals, and Meyka AI forecasts to clarify near-term direction for AYA.AX stock.
AYA.AX stock: Key market facts and intraday move
Artrya Limited (AYA.AX) is trading pre-market at A$3.21 on the ASX with a day low of A$3.15 and a day high of A$3.35. Market cap is A$384,644,000 and shares outstanding are 113,800,000. Volume today is 376,310 versus a 30-day average of 524,780, giving relative flow context.
AYA.AX stock: Financials and valuation metrics
AYA.AX shows EPS of -A$0.17 and a trailing PE of -19.88, reflecting current losses and growth investment. Book value per share is A$0.71 and cash per share is A$0.61, supporting a high current ratio of 37.11. Price-to-book sits near 4.76, and enterprise value is A$338,669,000, indicating premium valuation versus tangible equity.
AYA.AX stock: Technicals and trading signals
Momentum measures are neutral to mildly positive: RSI is 55.13 and MACD histogram is 0.03. Bollinger middle band is A$3.11 and ATR is A$0.27, so daily swings remain modest. On balance, the stock trades below its 50-day moving average, suggesting a short-term consolidation pattern rather than a breakout.
AYA.AX stock: Meyka AI grade and model forecast
Meyka AI rates AYA.AX with a score out of 100: 63.23 (Grade B, suggestion HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly A$3.05, quarterly A$4.36, and yearly A$7.41. Versus the current A$3.21, the quarterly forecast implies +35.80% upside and the yearly forecast implies +130.76% upside. Forecasts are model-based projections and not guarantees.
AYA.AX stock: Risks, opportunities and sector context
Key opportunities include scaling Salix sales in radiology networks and international regulatory clearances that would lift revenues. Risks include continued negative EPS, high R&D spend at 84.34% of revenue, and premium valuation metrics such as P/S which are extreme. Healthcare sector performance has lagged recently; the ASX healthcare index is down over three months, adding sector headwinds to AYA.AX stock.
AYA.AX stock: Analyst view, liquidity and news links
Recent third-party ratings show mixed signals: a company rating dated 25 Mar 2026 flagged a C / Sell on some fundamental metrics. Liquidity is moderate with average daily volume 524,780. For raw metrics and valuation context see Reuters summaries: Reuters: financial strength and Reuters: valuation. For our live tracking visit the Meyka AYA.AX page.
Final Thoughts
Short-term traders should note AYA.AX stock trades at A$3.21 with modest volume and mixed technicals. The company shows strong cash per share A$0.61 but negative EPS -A$0.17 and high R&D intensity. Meyka AI’s model projects A$7.41 in one year, implying +130.76% upside versus today’s price, while the one-month model of A$3.05 implies a -4.98% near-term dip. Our Meyka grade (63.23, B, HOLD) reflects balanced upside potential against execution and valuation risks. Investors should weigh clinical adoption milestones and revenue traction before increasing exposure. Forecasts are model-based projections and not guarantees, so monitor earnings updates and regulatory news for catalysts.
FAQs
What is the current price and market cap of AYA.AX stock?
AYA.AX stock trades at A$3.21 pre-market on 28 Mar 2026. Market capitalisation is A$384,644,000 with 113,800,000 shares outstanding. Volume today is 376,310 versus a 30-day average of 524,780.
What valuation and profitability metrics should I watch for AYA.AX stock?
Watch EPS (-A$0.17), PE (-19.88), price-to-book (4.76), and cash per share (A$0.61). Improvement in revenue growth and narrowing losses will be key to justify current multiples for AYA.AX stock.
What does Meyka AI forecast for AYA.AX stock?
Meyka AI’s forecast model projects quarterly A$4.36 and yearly A$7.41. Versus the current A$3.21, the yearly forecast implies +130.76% upside. Forecasts are model-based projections and not guarantees.
What are the main risks to AYA.AX stock performance?
Main risks include slow commercial roll-out of Salix, continued negative EPS, high R&D spending, and premium valuation metrics that increase sensitivity to missed milestones for AYA.AX stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)